Related Experiment Video
Updated: Oct 9, 2025
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Modulating Autoimmunity against LDL: Development of a Vaccine against Atherosclerosis
Timoteo Marchini1,2,3,4, Tijani Abogunloko1,2,4, Dennis Wolf1,2
1Cardiology and Angiology I, University Heart Center and Medical Center - University of Freiburg, Germany.
Insights
Immunomodulatory vaccination targeting low-density lipoprotein (LDL) and apolipoprotein B (ApoB) shows promise in dampening autoimmune responses and protecting against atherosclerosis. This approach enhances tolerance to atherosclerosis-specific antigens in preclinical models.
Area of Science:
- Cardiovascular Research
- Immunology
- Translational Medicine
Background:
- Atherosclerosis is a chronic inflammatory arterial disease causing plaque buildup, leading to myocardial infarction and stroke, major global causes of death.
- The pathology involves traditional risk factors, chronic inflammation, and a significant autoimmune response, including autoreactive T cells and autoantibodies against LDL and ApoB.
- Autoimmunity plays a crucial role in atherosclerosis development and progression.
Purpose of the Study:
- To review and discuss the mechanisms underlying immunomodulatory vaccination strategies for atherosclerosis.
- To explore the challenges and therapeutic opportunities associated with enhancing protective immunity against atherosclerosis.
- To summarize preclinical findings on vaccination with LDL, ApoB, or peptides for atherosclerosis treatment.
Main Methods:
- Review of preclinical observations and experimental data from the past 60 years.
- Analysis of immunomodulatory vaccination approaches using low-density lipoprotein (LDL), apolipoprotein B (ApoB), and their peptides.
- Discussion of mechanisms involving T cell responses, autoantibodies, and antigen tolerance in atherosclerosis models.
Main Results:
- Preclinical studies suggest immunomodulatory vaccination can specifically dampen autoimmune responses in atherosclerosis.
- Vaccination strategies have shown potential in enhancing tolerance to atherosclerosis-specific antigens.
- Experimental models demonstrate protective effects of these immunomodulatory approaches against atherosclerosis development.
Conclusions:
- Immunomodulatory vaccination represents a promising therapeutic strategy for atherosclerosis by targeting key autoimmune components.
- Further research into mechanisms, challenges, and optimization is needed to translate these findings into clinical applications.
- Enhancing protective immunity through vaccination offers a novel avenue for managing atherosclerosis and its cardiovascular consequences.
Abstract:
Atherosclerosis is a chronic inflammatory disease of the arterial wall that leads to the build-up of occluding atherosclerotic plaques. Its clinical sequelae, myocardial infarction and stroke, represent the most frequent causes of death worldwide. Atherosclerosis is a multifactorial pathology that involves traditional risk factors and chronic low-grade inflammation in the atherosclerotic plaque and systemically. This process is accompanied by a strong autoimmune response that involves autoreactive T cells in lymph nodes and atherosclerotic plaques, as well as autoantibodies that recognize low-density lipoprotein (LDL) and its main protein component apolipoprotein B (ApoB). In the past 60 years, numerous preclinical observations have suggested that immunomodulatory vaccination with LDL, ApoB, or its peptides has the potential to specifically dampen autoimmunity, enhance tolerance to atherosclerosis-specific antigens, and protect from experimental atherosclerosis in mouse models. Here, we summarize and discuss mechanisms, challenges, and therapeutic opportunities of immunomodulatory vaccination and other strategies to enhance protective immunity in atherosclerosis.
Related Concept Videos
01:26Atherosclerosis III: Management
01:38Inflammation
01:30Atherosclerosis I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures